1-6 of 6
Giordano Caponigro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Free
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Hengyu Lu, Bhavesh Pant, Matthew Shirley, Matthew J. Meyer, Minying Pu, Joanne Lim, Michael Fleming, LeighAnn Alexander, Ali Farsidjani, Matthew J. LaMarche, Susan Moody, Serena J. Silver, Giordano Caponigro, Darrin D. Stuart, Tinya J. Abrams, Peter S. Hammerman, Juliet Williams, Jeffrey A. Engelman, Silvia Goldoni, Morvarid Mohseni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2368–2380.
https://doi.org/10.1158/1535-7163.MCT-19-0170
Published: 02 December 2019
View articletitled, Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Open the PDF for Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Free
Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas Manuel Dunkl, Malika Kazic-Legueux, Anne Haberkorn, Eric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan E. Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huai-Xiang Hao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (7): 1323–1334.
https://doi.org/10.1158/1535-7163.MCT-18-0852
Published: 01 July 2019
View articletitled, SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Open the PDF for SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC

Free
Leila Dardaei, Hui Qin Wang, Manrose Singh, Paul Fordjour, Satoshi Yoda, Grainne Kerr, Jinsheng Liang, Yichen Cao, Yan Chen, Justin Gainor, Luc Friboulet, Ibiayi Dagogo-Jack, David Myers, Emma Labrot, David Ruddy, Melissa Parks, Dana Lee, Richard DiCecca, Susan Moody, Huaixiang Hao, Morvarid Mohseni, Matthew LaMarche, Juliet Williams, Keith Hoffmaster, Giordano Caponigro, Alice Shaw, Aaron Hata, Cyril Benes, Fang Li, Jeffrey Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A145.
https://doi.org/10.1158/1535-7163.TARG-17-A145
Published: 01 January 2018
View articletitled, Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC
Journal Articles

Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells

Free
Thomas Horn, Stéphane Ferretti, Nicolas Ebel, Angela Tam, Samuel Ho, Fred Harbinski, Ali Farsidjani, Matthew Zubrowski, Ensar Halilovic, Erick Morris, William R. Sellers, Robert Schlegel, Jens Wuerthner, Levi A. Garraway, Sébastien Jeay, Joel Greshock, Giordano Caponigro, Joseph Lehár
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-B04.
https://doi.org/10.1158/1535-7163.TARG-15-LB-B04
Published: 01 December 2015
View articletitled, Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells
Journal Articles

Abstract B18: High-dimensional combinations of cancer drugs to induce synthetic lethality in colorectal cancer

Free
Thomas Horn, Xiaobin Zhang, Samuel Ho, Levi Garraway, Robert Schlegel, Giordano Caponigro, Joseph Lehar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): B18.
https://doi.org/10.1158/1535-7163.PMS-B18
Published: 01 May 2014
View articletitled, Abstract B18: High-dimensional combinations of cancer drugs to induce synthetic lethality in colorectal cancer
Journal Articles

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Free
Sunkyu Kim, Alice Loo, Rajiv Chopra, Giordano Caponigro, Alan Huang, Sadhna Vora, Sudha Parasuraman, Steve Howard, Nicholas Keen, William Sellers, Christopher Brain
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): PR02.
https://doi.org/10.1158/1535-7163.TARG-13-PR02
Published: 01 November 2013
View articletitled, Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.